This may be the week to take a position - ahead of ASCO GI meeting
From seeking alpha transcript of Lilly's 2013 Financial Guidance Conference on Jan 4:
Now, I'd like to offer a preview of key events for the year. We anticipate that 2013 will be another eventful year for Lilly, with many Phase III trial completions, data presentations and regulatory submissions. Specifically, we anticipate a number of potential external data disclosures at scientific meetings. These include .... Disclosure at the ASCO GI meeting later this month of data from the positive Phase III trial of ramucirumab as monotherapy for second line gastric cancer. Presentation of data from the Phase III trial of ramucirumab in first line breast cancer. Note that the data we expect to receive in 2013 from this trial will be the final progression-free survival data and the interim overall survival data.....
More from Q&A (same conference):
So on ramucirumab gastric, we're still in the process of working through what might be the regulatory strategy. Clearly, this was upside surprise in terms of the data, as we had anticipated that this trial would really be a supportive trial to the combination second line gastric cancer trial that will report out later in '13. ...Clearly, we're enthusiastic and looking forward to these discussions with regulators and hopeful that we'll be able to have a very strong submission of the standalone indication, which is different than the initial expectation. And once we have clarity from regulators, if that's possible, what the timelines would be, if that's a standard or accelerated, we'll be able to provide you an update on that. That will probably be coming here later this year, probably in the first half, hopefully we will provide that update to you.